Eosinophilic Gastrointestinal Disorders
Dr. Marc Rothenberg is the Founder and Director of the Cincinnati Center for Eosinophilic Disorders (CCED), an international referral center and leader in the research, treatment and use of novel approaches in eosinophilic disorders, has made fundamental contributions in elucidating and treating these disorders.
The CCED was the first center dedicated to eosinophilic disorders and now serves as a global leader and role model for understanding, elucidating, and treating eosinophilic gastrointestinal disorders (EGIDs). The CCED researchers under Dr. Rothenberg’s direction conduct leading basic, translational, and clinical studies to determine the causes of eosinophilic disorders, develop better treatments, and find a cure. The CCED has substantially contributed to the understanding of the clinical, epidemiologic, genetic, and pathogenetic etiology of EGIDs. Investigator-initiated studies have fueled the development of novel therapeutics and served as the primary site for multi-center drug trials.
Dr. Rothenberg is also the founding Director and Principal Investigator of the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR), which is part of the Rare Disease Clinical Research Network (RDCRN) of the NIH. CEGIR involves 16 sites in the USA and partners with patient advocacy groups. CEGIR conducts innovative clinical trials, trains scholars through a mentoring program, and orchestrated pilot studies.
Select Related Publications
- Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation
- Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis
- Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis
- Eosinophilic esophagitis
- Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort
- The genetic etiology of eosinophilic esophagitis
- Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: multi-site study
- Eosinophilic gastrointestinal disease below the belt
- Role of genetics, environment, and their interactions in the pathogenesis of eosinophilic esophagitis
- Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium
- One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial
- Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial
